We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Windtree Therapeutics Inc (WINT) USD0.001

Sell:$0.35 Buy:$0.37 Change: $0.0139 (3.78%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$0.35
Buy:$0.37
Change: $0.0139 (3.78%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$0.35
Buy:$0.37
Change: $0.0139 (3.78%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics intended to address unmet medical needs in important cardiovascular care markets. The Company’s development programs are primarily focused on the treatment of cardiovascular diseases. Its lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients to treat early cardiogenic shock and acute heart failure (AHF). Its Rostafuroxin is an investigational drug product candidate being developed for the treatment of hypertension in patients with a specific genetic profile. Its heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a (SERCA2a) activators. The Company is also conducting early exploratory research to assess potential product candidates, including oral and intravenous SERCA2a activator heart failure compounds.

Contact details

Address:
2600 Kelly Rd Ste 100
WARRINGTON
18976-3652
United States
Telephone:
+1 (215) 4889300
Website:
https://windtreetx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
WINT
ISIN:
US97382D4025
Market cap:
$3.38 million
Shares in issue:
9.18 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Craig Fraser
    Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial Officer
  • Eric Curtis
    Chief Operating Officer, Senior Vice President
  • Diane Carman
    Senior Vice President, General Counsel, Corporate Secretary
  • Steven Simonson
    Senior Vice President, Chief Medical Officer
  • Jamie Mcandrew
    Chief Accounting Officer, Vice President, Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.